A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Plaque psoriasis; Psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms CIMPASI-2
  • Sponsors UCB
  • Most Recent Events

    • 27 Apr 2018 Based on data from phase 3 clinical development program consisting of CIMPASI-1, CIMPASI-2 and CIMPACT, UCB today announced that the European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a label extension for CIMZIA (certolizumab pegol), to include a new indication in adult patients with moderate-to-severe plaque psoriasis, according to an UCB media release.
    • 13 Apr 2018 Results assessing two phase 3 trials CIMPASI-1 and CIMPASI-2, was to evaluate the efficacy and safety of CZP compared with placebo in the treatment of moderate-to-severe chronic plaque psoriasis, were published in the Journal of the American Academy of Dermatology.
    • 16 Feb 2018 According to a UCB media release, data from a pooled sub-analysis of the studies CIMPASI-1, CIMPASI-2 and CIMPACT will be presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top